文献速递类风湿关节炎

多生物标志物疾病活动度评分与早期类风湿关节炎甲氨蝶呤失败后二线治疗选择

A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure.
PubMed 文献 · Arthritis Rheumatol · 2017-03-31

该研究分析157例甲氨蝶呤应答不足的早期类风湿关节炎患者,评估多生物标志物疾病活动度(MBDA)评分能否预测二线治疗应答。结果显示低MBDA评分者更可能对三联治疗应答,高MBDA评分者更可能对MTX联合英夫利西单抗应答。

要点

  • 低MBDA评分(<30)者三联治疗应答率88%,MTX联合英夫利西单抗仅18%(P=0.006)。
  • 高MBDA评分(>44)者三联治疗应答率35%,MTX联合英夫利西单抗58%(P=0.040)。
  • 以38为界,低评分者三联治疗应答79% vs 联合英夫利西单抗44%,高评分者36% vs 58%(P=0.001)。

核心结论

  • 在甲氨蝶呤应答不足的类风湿关节炎患者中,MBDA评分分类与后续治疗应答存在差异关联。
  • 甲氨蝶呤治疗后生化改善(较低MBDA评分)的患者更可能对三联治疗应答而非MTX联合英夫利西单抗。

研究设计与样本

  • 分析瑞典药物疗法(SWEFOT)试验中157例甲氨蝶呤应答不足(DAS28-ESR>3.2)的早期类风湿关节炎患者数据。
  • 患者随机接受三联治疗(MTX+柳氮磺吡啶+羟氯喹)或MTX联合英夫利西单抗,在随机化时分析MBDA评分对后续DAS28应答的预测作用。

主要发现

  • 157例患者中12%为低MBDA评分,32%为中等,56%为高。
  • 低MBDA评分者中88%对三联治疗应答,18%对MTX联合英夫利西单抗应答(P=0.006)。
  • 高MBDA评分者中35%对三联治疗应答,58%对MTX联合英夫利西单抗应答(P=0.040)。
  • 以38为界(29%患者低评分,71%高评分),低评分者三联治疗与联合英夫利西单抗应答率分别为79%和44%,高评分者分别为36%和58%(P=0.001)。
  • 临床和炎症标志物对三联治疗或MTX联合英夫利西单抗应答的预测能力较差。

关键数值与推荐

  • MBDA评分验证分类:低<30,中等30-44,高>44。
  • 二分分类:较低≤38,较高>38。
  • 甲氨蝶呤应答不足定义:DAS28-ESR>3.2。

临床怎么用

  • 对于甲氨蝶呤应答不足的早期类风湿关节炎患者,MBDA评分可能有助于选择二线治疗:低评分者倾向三联治疗,高评分者倾向MTX联合英夫利西单抗。
  • 该结果需进一步验证后才能常规用于临床决策。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether the Multi-Biomarker Disease Activity (MBDA) score predicts optimal add-on treatment in patients with early rheumatoid arthritis (RA) who were inadequate responders to MTX (MTX-IRs). METHODS: We analyzed data from 157 MTX-IRs (with a Disease Activity Score using the erythrocyte sedimentation rate [DAS28-ESR] >3.2) from the Swedish Pharmacotherapy (SWEFOT) trial who were randomized to receive triple therapy (MTX plus sulfasalazine plus hydroxychloroquine) versus MTX plus infliximab. The MBDA score as a predictor of the subsequent DAS28-based response to each second-line treatment was analyzed at randomization with the Breslow-Day test for 2 × 2 groups, using both validated categories (low [<30], moderate [30-44], and high [>44]) and dichotomized categories (lower [≤38] versus higher [>38]). RESULTS: Among the 157 patients, 12% had a low MBDA score, 32% moderate, and 56% high. Of those with a low MBDA score, 88% responded to subsequent triple therapy, and 18% responded to MTX plus infliximab (P = 0.006); for those with a high MBDA score, the response rates were 35% and 58%, respectively (P = 0.040). When using 38 as a cutoff for the MBDA score (29% patients with lower scores versus 71% with higher scores), the differential associations with response to triple therapy versus MTX plus infliximab were 79% versus 44% and 36% versus 58%, respectively (P = 0.001). Clinical and inflammatory markers had poorer predictive capacity for response to triple therapy or MTX plus infliximab. CONCLUSION: In patients with RA who had an inadequate response to MTX, the MBDA score categories were differentially associated with response to subsequent therapies. Thus, patients with post-MTX biochemical improvements (lower MBDA scores) were more likely to respond to triple therapy than to MTX plus infliximab. If confirmed, these results may help to improve treatment in RA.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Hambardzumyan K, Saevarsdottir S, Forslind K, et al. A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure. Arthritis Rheumatol. 2017. PMID: 27992691. doi:10.1002/art.40019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。